Literature DB >> 21172251

Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years.

May-Bente Bengtson1, Camilla Solberg, Geir Aamodt, Jostein Sauar, Jørgen Jahnsen, Bjørn Moum, Idar Lygren, Morten H Vatn.   

Abstract

BACKGROUND AND AIMS: To explore the change in risk among 1st degree relatives of ulcerative colitis (UC) and Crohn's disease (CD) for development of concordant disease in an incidence cohort followed for ten years. Furthermore, we wanted to compare familial and sporadic cases regarding clinical characteristics and the course of the disease.
METHODS: This population-based study included 421 patients with UC and 197 with CD enrolled from 1990 to 1994. Clinical characteristics and the number of 1st degree relatives of the patients were recorded continuously during ten years.
RESULTS: Age at diagnosis in CD patients (OR=0.95, 95% CI: 0.93-0.98) and cumulative relapse rate in UC patients (OR=4.91, 95% CI=1.16, 20.75) were significantly associated to familial clustering. Based on the calculated population prevalence of CD (262/100000) and UC (505/100000), the age-adjusted risk for development of concordant disease was 25.9 and 8.6 among siblings and parents of CD, respectively. In UC, the corresponding risks were 8.6 and 1.5. In the course of ten years the increase in risk was observed only among siblings (28%) and parents (97%) of UC, in contrast to no increase in CD. Moreover, the concordance for UC was high in three generations.
CONCLUSIONS: Our study confirmed the importance of genetic influence on the development of CD. Within an observation period of ten years, the increased concordance and relapse rate in familial UC, might point to a larger genetic component in UC than previously suggested.

Entities:  

Year:  2008        PMID: 21172251     DOI: 10.1016/j.crohns.2008.11.002

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  10 in total

1.  An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer.

Authors:  Bríd M Ryan; Roger K Wolff; Nicola Valeri; Mohammed Khan; Dillon Robinson; Alessio Paone; Elise D Bowman; Abbie Lundgreen; Bette Caan; John Potter; Derek Brown; Carlo Croce; Martha L Slattery; Curtis C Harris
Journal:  Cancer Epidemiol       Date:  2014-08-15       Impact factor: 2.984

2.  Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes.

Authors:  Katja Christodoulou; Anthony E Wiskin; Jane Gibson; William Tapper; Claire Willis; Nadeem A Afzal; Rosanna Upstill-Goddard; John W Holloway; Michael A Simpson; R Mark Beattie; Andrew Collins; Sarah Ennis
Journal:  Gut       Date:  2012-04-28       Impact factor: 23.059

3.  Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.

Authors:  Manuel A Rivas; Mélissa Beaudoin; Agnes Gardet; Christine Stevens; Yashoda Sharma; Clarence K Zhang; Gabrielle Boucher; Stephan Ripke; David Ellinghaus; Noel Burtt; Tim Fennell; Andrew Kirby; Anna Latiano; Philippe Goyette; Todd Green; Jonas Halfvarson; Talin Haritunians; Joshua M Korn; Finny Kuruvilla; Caroline Lagacé; Benjamin Neale; Ken Sin Lo; Phil Schumm; Leif Törkvist; Marla C Dubinsky; Steven R Brant; Mark S Silverberg; Richard H Duerr; David Altshuler; Stacey Gabriel; Guillaume Lettre; Andre Franke; Mauro D'Amato; Dermot P B McGovern; Judy H Cho; John D Rioux; Ramnik J Xavier; Mark J Daly
Journal:  Nat Genet       Date:  2011-10-09       Impact factor: 38.330

4.  The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada.

Authors:  Keeley L Rose; Philip M Sherman; Jane Cooke-Lauder; Mina Mawani; Eric I Benchimol; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Sanjay K Murthy; Geoffrey C Nguyen; Kate Lee
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

5.  Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017).

Authors:  Jesús K Yamamoto-Furusho; Andrea Sarmiento-Aguilar; Joel J Toledo-Mauriño; Katya E Bozada-Gutiérrez; Francisco J Bosques-Padilla; Manuel A Martínez-Vázquez; Virgilio Marroquín-Jiménez; Rosalva García-Figueroa; Christian Jaramillo-Buendía; Rosa M Miranda-Cordero; Jesús A Valenzuela-Pérez; Yolanda Cortes-Aguilar; Janett S Jacobo-Karam; Emilio F Bermudez-Villegas
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis.

Authors:  Zi-Jia Zhang; Hong-Lei Qu; Na Zhao; Jing Wang; Xiu-Yan Wang; Rong Hai; Bin Li
Journal:  Front Genet       Date:  2021-02-18       Impact factor: 4.599

7.  Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study.

Authors:  Sandre Svatun Lirhus; Marte Lie Høivik; Bjørn Moum; Karoline Anisdahl; Hans Olav Melberg
Journal:  Clin Epidemiol       Date:  2021-04-23       Impact factor: 4.790

Review 8.  Animal models to study acute and chronic intestinal inflammation in mammals.

Authors:  Janelle A Jiminez; Trina C Uwiera; G Douglas Inglis; Richard R E Uwiera
Journal:  Gut Pathog       Date:  2015-11-10       Impact factor: 4.181

9.  Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis.

Authors:  Damián García-Olmo; Gert Van Assche; Ignacio Tagarro; Mary Carmen Diez; Marie Paule Richard; Javaria Mona Khalid; Marc van Dijk; Dimitri Bennett; Suvi R K Hokkanen; Julián Panés
Journal:  Adv Ther       Date:  2019-10-26       Impact factor: 3.845

10.  Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.

Authors:  Giulia Orlando; Philip J Law; Kimmo Palin; Sari Tuupanen; Alexandra Gylfe; Ulrika A Hänninen; Tatiana Cajuso; Tomas Tanskanen; Johanna Kondelin; Eevi Kaasinen; Antti-Pekka Sarin; Jaakko Kaprio; Johan G Eriksson; Harri Rissanen; Paul Knekt; Eero Pukkala; Pekka Jousilahti; Veikko Salomaa; Samuli Ripatti; Aarno Palotie; Heikki Järvinen; Laura Renkonen-Sinisalo; Anna Lepistö; Jan Böhm; Jukka-Pekka Mecklin; Nada A Al-Tassan; Claire Palles; Lynn Martin; Ella Barclay; Albert Tenesa; Susan Farrington; Maria N Timofeeva; Brian F Meyer; Salma M Wakil; Harry Campbell; Christopher G Smith; Shelley Idziaszczyk; Timothy S Maughan; Richard Kaplan; Rachel Kerr; David Kerr; Daniel D Buchanan; Aung Ko Win; John Hopper; Mark Jenkins; Noralane M Lindor; Polly A Newcomb; Steve Gallinger; David Conti; Fred Schumacher; Graham Casey; Jussi Taipale; Jeremy P Cheadle; Malcolm G Dunlop; Ian P Tomlinson; Lauri A Aaltonen; Richard S Houlston
Journal:  Hum Mol Genet       Date:  2016-03-22       Impact factor: 5.121

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.